NCT06169059CompletedPhase 1
A Phase 1 Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic Characteristics After Multiple Administration of JC-013 and JLP-2004 in Healthy Adult Volunteers
Jeil Pharmaceutical Co., Ltd.1 site in 1 country60 target enrollmentStarted: October 5, 2023Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Enrollment
- 60
- Locations
- 1
- Primary Endpoint
- AUC last of JLP-2004
Study Overview
Brief Summary
To evaluate the safety and pharmacokinetic characteristics after multiple administration of JC-013 and JLP-2004
Detailed Description
A phase 1 clinical trial to compare and evaluate the safety and pharmacokinetic characteristics after multiple administration of JC-013 and JLP-2004 in healthy adult volunteers
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 19 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Healthy adult volunteers aged 19 years or older at the time of screening
- •At the time of screening, those who weigh more than 50.0 kg and have a body mass index (BMI) of 18.0 kg/m2 or more and 30.0 kg/m2 or less.
- •Those who do not have congenital or chronic diseases and have no pathological symptoms or findings as a result of internal medical examination (if necessary, electroencephalography, electrocardiogram, chest and stomach endoscopy, or gastrointestinal radiography)
- •Those who be considered suitable for clinical subjects according to the results of laboratory tests (hematology tests, blood chemistry tests, urine tests, serum tests, blood coagulation tests, urine drugs tests), physical examinations and 12-lead electrocardiography at the time of screening
- •Those who voluntarily decide to participate and agree in writing to comply with the subject compliance requirements during the clinical trial period after receiving a detailed explanation of this clinical trial and fully understanding it
Exclusion Criteria
- •Those who have current or past medical history of clinically significant liver, kidney, nervous system, mental, respiratory, endocrine, blood disease, tumor, genitourinary, cardiovascular, digestive, and musculoskeletal systems, as well as the following symptoms or history.
- •① Renal impairment
- •② Liver disorder
- •For women, pregnant women (Urine-HCG positive) or breastfeeding mother
- •Those who have clinically significant hypersensitivity reactions such as asthma, hives, allergies, etc. to the main ingredient (Pelubiprofen), additives, or other drugs (aspirin or other non-steroidal anti-inflammatory drugs (including COX-2 inhibitors)) and have a history of hypersensitivity reaction
- •Those with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
- •Those with a history of gastrointestinal disease (Crohn's disease, ulcer, acute or chronic pancreatitis, etc.) or gastrointestinal surgery (excluding simple appendectomy or hernia surgery) that may affect the absorption of clinical trial drugs
Arms & Interventions
Treatment(Experimental): JLP-2004
Experimental
Group I(Peroid I-comparator, Peroid II-JLP-2004), Group II(Period I-JLP-2004, Period II-Comparator)
Intervention: JLP-2004 (Drug)
Treatment(Experimental): JLP-2004
Experimental
Group I(Peroid I-comparator, Peroid II-JLP-2004), Group II(Period I-JLP-2004, Period II-Comparator)
Intervention: JC-013 (Drug)
Control(Active Comparator): JC-013
Active Comparator
Group I(Peroid I-comparator, Peroid II-JLP-2004), Group II(Period I-JLP-2004, Period II-Comparator)
Intervention: JLP-2004 (Drug)
Control(Active Comparator): JC-013
Active Comparator
Group I(Peroid I-comparator, Peroid II-JLP-2004), Group II(Period I-JLP-2004, Period II-Comparator)
Intervention: JC-013 (Drug)
Outcomes
Primary Outcomes
AUC last of JLP-2004
Time Frame: 24 hours
Cmax of JLP-2004
Time Frame: 24 hours
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
To Evaluate the Safety and Pharmacokinetic Characteristics After the Administration of JC-001 and JLP-1901Healthy AdultNCT06171880Jeil Pharmaceutical Co., Ltd.48
Completed
Phase 1
A Study of JNJ-70033093 (BMS-986177) in Healthy Chinese Adult ParticipantsHealthyNCT04569695Janssen Research & Development, LLC40
Completed
Phase 1
To Evaluate the Safety and Pharmacokinetic Characteristics After the Administration of JT-001, JT-002 and JLP-2008Healthy AdultNCT06165965Jeil Pharmaceutical Co., Ltd.48
Not yet recruiting
Phase 2
JK-1201I in Triple Negative Breast Cancer Patients with Brain MetastasesTriple Negative Breast Cancer (TNBC)Brain MetastasasesNCT06586866JenKem Technology Co., Ltd.25
Completed
Phase 1
A Study to Evaluate the Effect of Hepatic Impairment on JNJ-73763989Hepatic ImpairmentNCT04208386Janssen Sciences Ireland UC16